PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media56282010.18565/pharmateca.2023.6-7.101-109ProblemПроблемаReview ArticleAnemia in adult cancer patientsАнемия у взрослых онкологических пациентовhttps://orcid.org/0000-0001-9365-8554TeletaevaGulfiya M.ТелетаеваГульфия Мидхатовна
Russian Federation

Cand. Sci. (Med.), Oncologist, Department of Antitumor Drug Therapy

к.м.н., врач-онколог отделения противоопухолевой лекарственной терапии

drteletaeva@yahoo.comhttps://orcid.org/0000-0001-8533-1770DegtiarevaE. A.ДегтярёваЕ. А.
Russian Federation
drteletaeva@yahoo.comhttps://orcid.org/0000-0002-5026-0009ProtsenkoS. A.ПроценкоС. А.
Russian Federation
drteletaeva@yahoo.comhttps://orcid.org/0000-0002-8906-0370LatipovaD. Kh.ЛатиповаД. Х.
Russian Federation
drteletaeva@yahoo.comhttps://orcid.org/0000-0003-4538-8646SemenovaA. I.СеменоваА. И.
Russian Federation
drteletaeva@yahoo.comNovikA. V.НовикА. В.
Russian Federation
drteletaeva@yahoo.comhttps://orcid.org/0000-0002-4305-6691SemiglazovaT. Yu.СемиглазоваТ. Ю.
Russian Federation
drteletaeva@yahoo.comN.N. Petrov National Medical Research Center of OncologyНациональный медицинский исследовательский центр онкологии им. Н.Н. Петрова22072023306/71011092207202322072023Copyright ©; 2023, Bionika MediaCopyright ©; 2023, ООО «Бионика Медиа»2023Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/562820

Anemia is a frequent complication of the malignant process, negatively affecting the quality of life of the patient, as well as the results of anticancer treatment and the prognosis of the disease in general. The pathogenesis of anemia in a malignant process is quite complex and is attributable both to the presence of the tumor itself and to the ongoing antitumor treatment. This review summarizes current ideas about the causes and mechanisms of anemia in cancer patients, discusses the diagnostic algorithm and key methods for correcting this condition.

Анемия является частым осложнением злокачественного процесса, негативно влияя на качество жизни пациента, а также на результаты противоопухолевого лечения и прогноз заболевания в целом. Патогенез анемии при злокачественном процессе достаточно сложен и обусловлен как наличием самой опухоли, так и проводимым противоопухолевым лечением. В настоящем обзоре обобщены современные представления о причинах и механизмах развития анемии у онкологических пациентов, изложены алгоритм диагностики и ключевые методы коррекции данного состояния.

cancer-related anemiaanemia of chronic diseaseschemotherapy-induced anemiablood transfusionserythropoietinsiron preparationsанемия при злокачественных новообразованияханемия хронических заболеванийхимиоиндуцированная анемиягемотрансфузииэритропоэтиныпрепараты железаLudwig H., Van Belle S., Barrett-Lee P., et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293–306. Doi: 10.1016/j.ejca.2004.06.019.Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11–26. Doi: 10.1016/j.amjmed.2003.12.008.Tas F., Eralp Y., Basaran M., et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25(4):371–79. Doi: 10.1097/00000421-200208000-00011.Dicato M. Anemia in cancer: some pathophysiological aspects. Oncologist. 2003;8(Suppl. 1):19–21. Doi: 10.1634/theoncologist.8-suppl_1-19.Escobar Alvarez Y., de Las Penas Bataller R., Perez Altozano J., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. Doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.Патофизиология: учебник: в 2 т. Под ред. В.В. Новицкого, Е.Д. Гольдберга, О.И. Уразовой. 4-е изд., перераб. и доп. М., 2010. Т. 2. 640 с., илл. [Pathophysiology: textbook: in 2 volumes, Ed. V.V. Novitsky, E.D. Goldberg, O.I. Urazova. 4th ed., revised. and additional. Moscow, 2010. Vol. 2. 640 p., ill. (In Russ.)].Кулибаба Т.Г., Пчелин И.Ю., Слепых Л.А. Особенности анемического синдрома у онкологических пациентов. Juvenis Sci. 2018;9:10–6. [Kulibaba T.G., Pchelin I.Yu., Slepykh L.A. Features of anemic syndrome in cancer patients. Juvenis Sci. 2018;9:10–6. (In Russ.)]. Doi: 10.32415/jscientia.2018.09.02.Busti F., Marchi G., Ugolini S., et al. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018;11(4):94. Doi: 10.3390/ph11040094.Lv Y., Lau W.Y., Li Y., et al. Hypersplenism: History and current status. Exp Ther Med. 2016;12(4):2377–82. Doi: 10.3892/etm.2016.3683..Gangat N., Wolanskyj A.P. Anemia of chronic disease. Semin Hematol. 2013;50(3):232–38. Doi: 10.1053/j.seminhematol.2013.06.006. Erratum in: Semin Hematol. 2014;51(2):e1.Weiss G., Ganz T., Goodnough L.T. Anemia of inflammation. Blood. 2019;133(1):40–50. Doi: 10.1182/blood-2018-06-856500.Goodnough L.T., Nemeth E., Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–61. Doi: 10.1182/blood-2010-05-286260.Jewell U.R., Kvietikova I., Scheid A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312–14.Puthenparambil J., Lechner K., Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010;122(7–8):229–36. Doi: 10.1007/s00508-010-1319-z.Kamesaki T. [Autoimmune hemolytic anemia as a paraneoplastic syndrome associated with solid tumors]. Rinsho Ketsueki. 2015;56(7):778–84. Japanese. Doi: 10.11406/rinketsu.56.778.Terán Brage E., Fonseca Santos M. et al. Autoimmune Haemolytic Anaemia Due to Cold Antibodies in a Renal Cancer Patient. Case Rep Oncol. 2022;15(2):507–14. Doi: 10.1159/000524592.Lechner K., Obermeier H.L. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Med (Baltimore). 2012;91(4):195–205. Doi: 10.1097/MD.0b013e3182603598.Thomas M.R., Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021;137(10):1310–17. Doi: 10.1182/blood.2019003810.Lam R., Tarangelo N., Wang R., et al. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. Oncologist. 2022;27(9):751–59. Doi: 10.1093/oncolo/oyac093.Madeddu C., Neri M., Sanna E., et al. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. J Exp Pharmacol. 2021;13:593–611. Doi: 10.2147/JEP.S262349.Vazquez L., Arnaud A. Hematological Toxicity Induced by Bone Metastasis Radiation Therapy. In: Sergi C.M., editor. Metastasis [Internet]. Brisbane (AU): Exon Publications; 2022 May 3. Chapter 8. Available from: https://www.ncbi.nlm.nih.gov/books/NBK580874. Doi: 10.36255/exon-publications.metastasis.hematological-toxicity.Jefferies S., Rajan B., Ashley S., et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol. 1998;48(1):23–7. Doi: 10.1016/s0167-8140(98)00024-3. [PMID: 9756168].Weigl A., Kohler N., Monsef I., et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;2017(4):CD012633. Doi: 10.1002/14651858.CD012633.Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–59. Doi: 10.1172/JCI117840.Kimber C., Patterson J.F., Weintraub L.R. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA. 1967;202(10):935–8.Schade S.G., Cohen R.J., Conrad M.E. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–74. Doi: 10.1056/NEJM196809262791302.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hematopoietic Growth Factors (Version 2.2023). URL: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.Turner J., Parsi M., Badireddy M. Anemia. 2022 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan.Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63(1):25–36. Doi: 10.1016/j.ijrobp.2005.04.049.Teicher B.A., Holden S.A., al-Achi A., Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50(11):3339–44.Rakotomalala A., Escande A., Furlan A., et al. Hypoxia in Solid Tumors: How Low Oxygenation Impacts the «Six Rs» of Radiotherapy. Front Endocrinol (Lausanne). 2021;12:742215. Doi: 10.3389/fendo.2021.742215.Dubsky P., Sevelda P., Jakesz R., et al. Austrian Breast and Colorectal Cancer Study Group. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14(7):2082–87. Doi: 10.1158/1078-0432.CCR-07-2068.Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 1998;174(Suppl. 4):31–4.Орлова Р.В., Гладков О.А., Кутукова С.И. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Злокачественные опухоли: Практические рекомендации RUSSCO. Злокачественные опухоли. 2022;12(3s2-2):19–25. [Orlova R.V., Gladkov O.A., Kutukova S.I., et al. Practical recommendations for the treatment of anemia in malignant neoplasms. Malignant Tumors: RUSSCO Practice Guidelines. Malignant tumors. 2022;12(3s2-2):19–25. (In Russ.)]. Doi: 10.18027/2224-5057-2022-12-3s2-19-25.Aapro M., Beguin Y., Bokemeyer C., et al. ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv96–110. Doi: 10.1093/annonc/mdx758. Erratum in: Ann Oncol. 2018;29(Suppl. 4):iv271.World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Published 2011. URL: https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?ua=1.Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.Aapro M., Beguin Y., Bokemeyer C., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. Doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.Приказ Минздрава РФ от 25 ноября 2002 г. № 363 «Об утверждении Инструкции по применению компонентов крови». [Order of the Ministry of Health of the Russian Federation dated November 25, 2002 No. 363 «On Approval of the Instructions for the Use of Blood Components». (In Russ.)]. URL: http://www.consultant.ru/document/cons_doc_LAW_40315/.Khorana A.A., Francis C.W., Blumberg N., et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–81. Doi: 10.1001/archinte.168.21.2377.Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(Suppl. 3):12–8. Doi: 10.1634/theoncologist.2011-S3-12.Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia. Am. J. Hematol. 2014;89(2):203–12. Doi: 10.1002/ajh.23628.Tonia T., Mettler A., Robert N., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407. Doi: 10.1002/14651858.CD003407.pub5.McKoy J.M., Stonecash R.E., Cournoyer D., et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754–62. Doi: 10.1111/j.1537-2995.2008.01749.x.Ludwig H., Crawford J., Osterborg A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27(17):2838–47. Doi: 10.1200/JCO.2008.19.1130.Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010;102(2):301–15. Doi: 10.1038/sj.bjc.6605498.Gergal Gopalkrishna Rao S.R., Bugazia S., Dhandapani T.P.M., et al. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. Cureus. 2021;13(9):e17835. Doi: 10.7759/cureus.17835.Epoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf.Darbepoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103951s5378lbl.pdf.Ludwig H., Aapro M., Bokemeyer C., et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45(9):1603–15. Doi: 10.1016/j.ejca.2009.02.003.Petrelli F., Borgonovo K., Cabiddu M., et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138(2):179–87. Doi: 10.1007/s00432-011-1072-3.Buchrits S., Itzhaki O., Avni T., et al. Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022;11(14):4156. doi: 10.3390/jcm11144156.Tang G.H., Dhir V., Scheer A.S., et al. Intravenous iron versus oral iron or observation for gastrointestinal malignancies: a systematic review. Eur J Gastroenterol Hepatol. 2019;31(7):799–808. Doi: 10.1097/MEG.0000000000001433.Jurado R.L. Iron, infections, and anemia of inflammation. Clin. Infect. Dis. 1997;25(4):888–95. doi: 10.1086/515549.Carver P.L. The Battle for Iron between Humans and Microbes. Curr Med Chem. 2018;25(1):85–96. Doi: 10.2174/0929867324666170720110049.Litton E., Xiao J., Ho K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822. Doi: 10.1136/bmj.f4822.